Rajesh Singh

Rajesh Singh is a Senior Professor at Morehouse School of Medicine, where his research integrates pharmacology, medicinal chemistry, and oncology to advance cancer therapeutics. His work focuses on drug discovery, therapeutic targets in prostate and breast cancer, and the molecular mechanisms of epithelial-to-mesenchymal transition. Recent breakthroughs include identifying zerumbone-mediated CD1d inhibition in triple-negative breast cancer, developing the MammOnc-DB platform for breast cancer target discovery, and applying artificial intelligence to pharmacogenomics, CRISPR gene editing, and multi-omics analyses in pancreatic cancer. He has also explored nature-inspired anticancer agents, such as phytochemicals and thiazolidinedione derivatives. His contributions have been recognized with a $852,000 award for repurposing thymoquinone against metastatic castration-resistant prostate cancer, underscoring his commitment to translating basic research into precision oncology solutions.